These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 21353954)

  • 1. Equal efficacy of a generic piperacillin/tazobactam formulation: results of a local screening protocol.
    Tschudin-Sutter S; Frei R; Widmer AF
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):286-7. PubMed ID: 21353954
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum bactericidal activity of piperacillin/tazobactam against Staphylococcus aureus, piperacillin-susceptible and piperacillin-resistant Escherichia coli and Pseudomonas aeruginosa.
    Lemmen SW; Zolldann D; Klik S; Lütticken R; Kümmerer K; Häfner H
    Chemotherapy; 2004 Apr; 50(1):27-30. PubMed ID: 15084802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More potency assay results for generic non-USA lots of piperacillin/tazobactam and initial reports for generic meropenem compounds marketed in the USA.
    Jones RN; Sader HS; Flamm RK; Watters AA
    Diagn Microbiol Infect Dis; 2013 May; 76(1):110-2. PubMed ID: 23490010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn, Wyeth) formulation.
    Jones RN; Fritsche TR; Moet GJ
    Diagn Microbiol Infect Dis; 2008 May; 61(1):76-9. PubMed ID: 18221852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanded studies of piperacillin/tazobactam formulations: variations among branded product lots and assessment of 46 generic lots.
    Moet GJ; Watters AA; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2009 Nov; 65(3):319-22. PubMed ID: 19822271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relevance of various animal models of human infections to establish therapeutic equivalence of a generic product of piperacillin/tazobactam.
    Agudelo M; Rodriguez CA; Zuluaga AF; Vesga O
    Int J Antimicrob Agents; 2015 Feb; 45(2):161-7. PubMed ID: 25481459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro synergy studies based on tazobactam/piperacillin against clinical isolates of metallo-beta-lactamase-producing Pseudomonas aeruginosa.
    Fujimura S; Takane H; Nakano Y; Watanabe A
    J Antimicrob Chemother; 2009 Nov; 64(5):1115-6. PubMed ID: 19744981
    [No Abstract]   [Full Text] [Related]  

  • 8. Irreproducible piperacillin/tazobactam minimum inhibitory concentrations in microdilution tests with Escherichia coli strains.
    Thomson KS; Black J; Moland ES; Reuben J; Wiles T; Brasso W
    Int J Antimicrob Agents; 2008 Jan; 31(1):83-5. PubMed ID: 17996426
    [No Abstract]   [Full Text] [Related]  

  • 9. [In vitro interaction of tazobactam/piperacillin combined with aminoglycosides against Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli AND Staphylococcus aureus].
    Yamada H; Takahata M; Minami S
    Jpn J Antibiot; 2002 Feb; 55(1):61-6. PubMed ID: 11977921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microbiological equivalence of bacteriostatic and bactericidal activities of the sera from healthy volunteers receiving generic piperacillin/tazobactam (Pipertaz) and original piperacillin/tazobactam (Tazocin).
    Thamlikitkul V; Tiengrim S; Chalermsri C; Sae-Jong R; Suddhichupaiboon S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S196-202. PubMed ID: 21721447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy of automated and manual systems for susceptibility testing of Pseudomonas aeruginosa to piperacillin and piperacillin-tazobactam.
    Gagliotti C; Sarti M; Sabia C; Gargiulo R; Rossolini GM; Carillo C; Cassani C; Cipolloni AP; Pedna F; Rossi MR; Incerti SS; Testa G; Venturelli C; Moro ML
    New Microbiol; 2011 Jan; 34(1):97-9. PubMed ID: 21344153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against Pseudomonas aeruginosa and Escherichia coli.
    Bergen PJ; Bulitta JB; Sime FB; Lipman J; McGregor MJ; Millen N; Paterson DL; Kirkpatrick CMJ; Roberts JA; Landersdorfer CB
    Diagn Microbiol Infect Dis; 2018 May; 91(1):69-76. PubMed ID: 29395712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
    Erdem I; Kucukercan M; Ceran N
    Chemotherapy; 2003 Dec; 49(6):294-7. PubMed ID: 14671429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population analysis of Escherichia coli isolates with discordant resistance levels by piperacillin-tazobactam broth microdilution and agar dilution testing.
    Shubert C; Slaughter J; Creely D; van Belkum A; Gayral JP; Dunne WM; Zambardi G; Shortridge D
    Antimicrob Agents Chemother; 2014; 58(3):1779-81. PubMed ID: 24342642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations.
    Liu Q; Rand K; Derendorf H
    Int J Antimicrob Agents; 2004 May; 23(5):494-7. PubMed ID: 15120729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In the literature. Piperacillin-tazobactam and extended-spectrum β-lactamase--producing Escherichia coli.
    Clin Infect Dis; 2013 Nov; 57(10):iii-iv. PubMed ID: 24308040
    [No Abstract]   [Full Text] [Related]  

  • 17. In vivo pharmacodynamics of piperacillin/tazobactam: implications for antimicrobial efficacy and resistance suppression with innovator and generic products.
    Rodriguez CA; Agudelo M; Zuluaga AF; Vesga O
    Int J Antimicrob Agents; 2017 Feb; 49(2):189-197. PubMed ID: 27988068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa.
    Zhanel GG; Mayer M; Laing N; Adam HJ
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2228-30. PubMed ID: 16723591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Escherichia coli with Current Automated Susceptibility Test Systems.
    Monogue ML; Tanner LK; Brecher SM; Aslanzadeh J; Nicolau DP
    Infect Control Hosp Epidemiol; 2017 Mar; 38(3):379-380. PubMed ID: 28069100
    [No Abstract]   [Full Text] [Related]  

  • 20. Susceptibility survey of piperacillin/tazobactam and some beta-lactam comparators in Italy.
    Stefani S; Bonfiglio G; Bianchi C; Zollo A; Nicoletti G
    Drugs Exp Clin Res; 1998; 24(2):105-13. PubMed ID: 9675551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.